News Articles Archives - Page 3 of 4 - Triumvira Immunologics | Engineered T Cell Therapies
Discussion on TAC01-HER2 Therapy
Benjamin L. Schlechter, MD, senior physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors.
TACTIC-2 Trial Findings
The ongoing, phase 1/2 TACTIC-2 trial (NCT04727151) is evaluating the efficacy and safety of autologous TAC01-HER2 T-cell therapy in patients with HER2-positive breast, colorectal, gall bladder, gastroesophageal junction (GEJ), gastric, esophageal, lung, and ovarian cancers.
- Interim findings from this trial, presented at the 2023 ASCO Annual Meeting, showed:
- 2 partial responses to the therapy, one in a patient with refractory GEJ cancer and one in a patient with refractory gastric cancer.
- In the patients with gastric, GEJ, or esophageal cancer:
- Disease control rate (DCR): 83%
- Overall response rate: 33%
- In heavily pretreated patients, DCR was 67%.
- One dose-limiting toxicity (DLT), grade 3 pneumonitis, was observed and 1 patient had grade 3 cytokine release syndrome.
- No incidence of immune effector cell–associated neurotoxicity syndrome has been reported.
Advances in Cancer Immunotherapy
Cancer treatments that work with the immune system are making great strides, with Keytruda from Merck being among the best known. Still, there is much work to be done in developing unprecedented new treatments and treatments that can combine with existing ones for enhanced effectiveness.
Dr. Paul Lammers, CEO of Triumvira Immunologics, discusses the company's efforts in this area.
Lammers’ Insights on Leadership
In this episode, we talk with Paul Lammers about leadership in the biotech industry, stressing the significance of transparent and open communication between leaders and employees, particularly during times of change. Lammers emphasizes the challenges of balancing innovation with regulatory constraints and the importance of investing in talent development to foster both employee growth and organizational success.
The Future of Cell Therapies
Cell therapies are revolutionizing cancer treatment, with Triumvira developing autologous and allogeneic T-Cell therapies that aim to address the limits of existing options. The focus is on making these therapies effective for both hematologic and solid tumors.
We spoke to Paul Lammers about the robustness of the company's platform technology.
Overview of the JP Morgan Healthcare Conference
In an analysis, speakers discussed updates their company presented at the recent JP Morgan Healthcare Conference, a pivotal event for biotech deal-making. Notably, Dr. Robert Ross, CEO of Surface Oncology, and Dr. Paul Lammers from Triumvira shared insights on the industry's trajectory and challenges.
Impact of Silicon Valley Bank's Collapse
The collapse of Silicon Valley Bank will significantly affect early-stage biotechnology companies, leaving a funding void, as many had banked there, including companies developing treatments for various conditions.
Advancements in Personalized Medicine
Dr. Paul Lammers highlights Triumvira’s work on personalized medicine for solid tumors through its autologous approach with the TAC (T Cell Antigen Coupler) technology, aiming to broaden treatment options for high unmet needs in various cancers.